← FDA DRUG APPROVALS

FDA NDA · NDA022318

SEVELAMER CARBONATE

Sponsor: GENZYME

APPLICATION
NDA022318
TYPE
NDA
ORIGINAL APPROVAL
2009-08-12
LATEST ACTION
2020-04-30
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

RENVELA · ReferenceDiscontinued
SEVELAMER CARBONATE 2.4GM/PACKET · FOR SUSPENSION · ORAL
RENVELA · ReferenceDiscontinued
SEVELAMER CARBONATE 800MG/PACKET · FOR SUSPENSION · ORAL

Approval history

2020-04-30Labeling · Supplement 12 · standard — Letter ↗AP
2016-11-25Efficacy · Supplement 8 · priority — Letter ↗AP
2016-03-09Labeling · Supplement 6 · standard — Label ↗AP
2014-11-26Labeling · Supplement 5 · standard — Label ↗AP
2011-06-16Labeling · Supplement 3 · unknown — Label ↗AP
2009-08-12Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →